The study examined a Manchester pilot of the programme, which will see 12- and 13-year old-girls being vaccinated against the cancer-causing human papillomavirus.
In the Manchester trial, a total of 2,817 girls were offered the three-dose vaccination. Of these, 70.6 per cent had the first jab and 68.5 per cent had the second. The University of Manchester study finished before the third jab but researchers warned the vaccine would not be effective unless girls had all three.
The study also highlighted the main reasons parents refused to give consent to the vaccination.
These included a lack of information on the vaccinations and long-term safety. A few parents said their children were too young to be at risk and others were worried it might encourage teenagers to have sex.
Register Now to Continue Reading
Thank you for visiting Children & Young People Now and making use of our archive of more than 60,000 expert features, topics hubs, case studies and policy updates. Why not register today and enjoy the following great benefits:
What's Included
-
Free access to 4 subscriber-only articles per month
-
Email newsletter providing advice and guidance across the sector
Already have an account? Sign in here
